Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hADME and Absolute Bioavailability Trial of BI 1569912 in Healthy Male Subjects
NCT06520553Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 1569912, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction Excreted in Urine up to 14 days, Fraction Excreted in Faeces up to 14 days and 2 more. Started Aug 2024; status: completed.
02
Drugs
BI 1569912
Beyond the preview
Go deeper on NCT06520553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520553.